Viatris (WBO:MYL) Change In Receivables : €73 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Viatris Change In Receivables?

Viatris's change in receivables for the quarter that ended in Dec. 2023 was €75 Mil. It means Viatris's Accounts Receivable declined by €75 Mil from Sep. 2023 to Dec. 2023 .

Viatris's change in receivables for the fiscal year that ended in Dec. 2023 was €72 Mil. It means Viatris's Accounts Receivable declined by €72 Mil from Dec. 2022 to Dec. 2023 .

Viatris's Accounts Receivable for the quarter that ended in Dec. 2023 was €2,589 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Viatris's Days Sales Outstanding for the three months ended in Dec. 2023 was 67.15.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Viatris's liquidation value for the three months ended in Dec. 2023 was €-20,340 Mil.

Viatris Change In Receivables Historical Data

The historical data trend for Viatris's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Change In Receivables Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-18.00

64.69

52.48

-226.84

72.08

Viatris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-320.21	200.81	-134.57	-67.46	74.64

Viatris Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €73 Mil.

Viatris (WBO:MYL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Viatris's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2589.425	/	3518.804	*	91
=	67.15

2. In Ben Graham's calculation of liquidation value, Viatris's accounts receivable are only considered to be worth 75% of book value:

Viatris's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1086.095	-	24958.998	+	0.75 * 2589.425	+	0.5 * 3181.715
=	-20,340

Viatris Change In Receivables Related Terms

Thank you for viewing the detailed overview of Viatris's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (WBO:MYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines